Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
0.9538
-0.0140 (-1.45%)
At close: Dec 31, 2025, 4:00 PM EST
1.000
+0.046 (4.84%)
After-hours: Dec 31, 2025, 7:59 PM EST
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2024. The number of employees increased by 12 or 200.00% compared to the previous year.
Employees
18
Change
12
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,387,388
Market Cap
94.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 12 | 200.00% |
| Dec 31, 2018 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRDL News
- 4 weeks ago - New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 - Newsfile Corp
- 2 months ago - Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 - Newsfile Corp
- 5 months ago - Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference - Newsfile Corp
- 5 months ago - Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile Corp
- 5 months ago - Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile Corp